TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19757215
Drug: Sorafenib in
Normalized name: Product containing sorafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib in patients with prior cytokine therapy
Study: 19757215
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in patients with prior cytokine therapy
Study: 18755514
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg daily, flexible-dose)
Study: 16780494
Drug: 1072-nm light
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1072-nm light treatment
Study: 4067130
Drug: 0.5 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ppm of sulfur dioxide (SO2) via oral inhalation
Study: 4067130
Drug: 0.5 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ppm of sulfur dioxide (SO2) via oronasal inhalation (face mask)
Study: 30240978
Drug: Computer-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based cognitive-behavioral therapy (CBT4CBT) plus treatment as usual (TAU)
Study: 30240978
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment as usual (TAU)
Study: 24439741
Drug: Interrupted transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted transdermal suture
Study: 22960288
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg, single subcutaneous injection)
Study: 18799552
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (23-valent pneumococcal polysaccharide vaccine)
Study: 15707442
Drug: Cognitive coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive coping intervention administered over three consecutive days in 20-30 minute sessions.
Study: 12125806
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT)
Study: 2140370
Drug: TCMP‐80 (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCMP‐80 (0.01 mg/kg to 10 mg/kg)
Study: 30945492
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (puncturing specific acupoints below the spinous processes from T3 to T12, once every other day for 8 weeks)
Study: 30945492
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (omeprazole capsules 20 mg, twice a day for 8 weeks)
Study: 26028518
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel (70 mg/m² on day 2) and estramustine (10 mg/kg per day on days 1-5, every 3 weeks)
Study: 17265078
Drug: Tiagabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (15 mg/day)
Study: 14692927
Drug: Post punch‐grafting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post punch‐grafting topical application of fluocinolone acetonide 0.1% (group II)
Study: 11009194
Drug: Cued physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cued physical therapy
Study: 11009194
Drug: Non-cued physical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cued physical therapy
Study: 9180192
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg and 20 microg doses at 0 and 6 months
Study: 9180192
Drug: Three 10-microg
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 10-microg doses at 0, 1, and 6 months
Study: 8238144
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with fourfold thromboxane B2 reduction
Study: 27798902
Drug: Trastuzumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (8 mg/kg) and Paclitaxel (90 mg/m2) every three weeks
Study: 20225477
Drug: Gel-to-foam dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel-to-foam dentifrice (Aquafresh Iso-active)
Study: 17381486
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5 g)
Study: 15367249
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of bupropion SR daily and PTC (n=382)
Study: 15367249
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of bupropion SR daily and PTC (n=383)
Study: 15367249
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of bupropion SR daily and TM (n=381)
Study: 15367249
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of bupropion SR daily and TM (n=378)
Study: 11318882
Drug: Tizanidine hydrochloride
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine hydrochloride tablets (median daily dose of 14 mg, mean 13.5 mg, SD 4.3, range 4 to 20 mg, divided over three doses per day)
Study: 11318882
Drug: Tizanidine hydrochloride
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine hydrochloride tablets
Study: 9840539
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber supplement
Study: 31133494
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive monthly treatments with selamectin (5.25–6.60 mg/kg) and sarolaner (0.88–1.10 mg/kg) on Days 0, 30, and 60
Study: 31133494
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with fluralaner (34.71–43.08 mg/kg) on Day 0 and placebo on Days 30 and 60
Study: 28403598
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with Prulifloxacine, 400 mg/day for 5 days
Study: 28403598
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of D-mannose and NAC therapy, two vials/day for 7 days
Study: 24267043
Drug: Cayenne pepper
Normalized name: Cayenne pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cayenne pepper (500 mg, 1.25 mg capsaicin)
Study: 24267043
Drug: Evodiamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evodiamine (500 mg)
Study: 22384541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Wenshen Yangxue Granule (WSYXG) and Clomifene Citrate (CC)
Study: 16427437
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (120 to 150 mg a day continuous infusion)
Study: 16427437
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prophylactic hypervolemic and hemodilution therapy plus nimodipine)
Study: 2961362
Drug: L-714,465 (0-4%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-714,465 (0-4%)
Study: 28156253
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in patients with severe carotid stenosis (≥ 70%)
Study: 28156253
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in patients with less than 70% stenosis (< 70%)
Study: 22906959
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine (Gardasil; Merck)
Study: 22906959
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine (Cervarix; GlaxoSmithKline)
Study: 18540910
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg/d) + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Study: 18540910
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg/d) + BRENDA + medication clinic
Study: 18540910
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg/d) + medication clinic with limited therapeutic content
Study: 18540910
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Study: 18540910
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + BRENDA + medication clinic
Study: 18540910
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + medication clinic with limited therapeutic content
Study: 12925457
Drug: HEPACOAT stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEPACOAT stent with aspirin alone
Study: 6337611
Drug: mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (30 to 90 mg)
Study: 6337611
Drug: maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline (75 to 225 mg)
Study: 6337611
Drug: placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (1 to 3 capsules)
Study: 25649338
Drug: Percutaneous electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous electric neurostimulation (PENS) of dermatome T7 (12 sessions of 30 minutes weekly) associated with a 1,200 Kcal/day diet
Study: 23179965
Drug: THC (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0.015 to 0.05 mg/kg)
Study: 21834670
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical povidone-iodine
Study: 19366970
Drug: Taspoglutide 5
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 5 mg once weekly
Study: 22937895
Drug: Taspoglutide 10
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 10 mg once weekly
Study: 22937895
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg once weekly
Study: 19366970
Drug: Taspoglutide 10
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 10 mg once every 2 weeks
Study: 19366970
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg once every 2 weeks
Study: 8963158
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/ml, single dose)
Study: 8963158
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/ml, one drop in each eye twice daily for two weeks)
Study: 6345281
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid 12 mg/kg
Study: 30970218
Drug: ω‐3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 supplementation (3 g eicosapentaenoic acid, 2 g docosahexaenoic acid)
Study: 26589401
Drug: Supervised rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised rehabilitation therapy (weekly sessions with facial exercises and massages, daily facial exercises at home)
Study: 26589401
Drug: Daily homework
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily homework manual for ordinary postoperative facial mimic exercises (autonomously at home)
Study: 19091127
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day of astaxanthin
Study: 12094249
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 30 mg/m² administered from days 1 to 3 and days 8 to 10, along with vincristine, prednisolone, cyclophosphamide, and L‐asparaginase, followed by three courses of consolidation and four courses of intensification
Study: 2006664
Drug: Diuretics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics with or without methyldopa
Study: 31501124
Drug: Probiotic tablets
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablets containing Streptococcus salivarius M18 and Lactobacillus acidophilus with regular oral hygiene
Study: 31501124
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral hygiene alone
Study: 29669596
Drug: 12.5-μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5-μg sublingual tablets of misoprostol
Study: 29669596
Drug: Placebo sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablets and 25-μg vaginal tablets of misoprostol
Study: 15980034
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with microvascular complications and glucose level <7.7 mmol/L
Study: 10578025
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (Group B)
Study: 10578025
Drug: Both enteral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both enteral and parenteral nutrition (Group C)
Study: 7485307
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (0.5 mg intracervically)
Study: 1691900
Drug: Medium-molecular-weight hydroxyethyl
Normalized name: chitosan medium molecular weight (200-800 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-molecular-weight hydroxyethyl starch solution
Study: 1691900
Drug: Low-molecular-weight hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight hydroxyethyl starch solution
Study: 374194
Drug: Oral BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCG vaccine
Study: 8835890
Drug: Acid-reducing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-reducing therapy (all drugs)
Study: 1575589
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg, intramuscular injection)
Study: 1575589
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injection)
Study: 3909329
Drug: Aztreonam, 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam, 2.0 g every 8‐12 hr
Study: 29370583
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in ER-positive or luminal tumours
Study: 22990330
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg almorexant once daily for 9 days
Study: 11190775
Drug: 0.1% dimetindene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dimetindene maleate spray (Fenistil Nasal Dosierspray)
Study: 3057674
Drug: Oral prazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prazosin (2 mg twice daily) for three weeks
Study: 26376765
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of mupirocin (three times a day)
Study: 26376765
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of mupirocin (once a day)
Study: 24354929
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg daily) plus Ezetimibe (10 mg daily)
Study: 20302811
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management (non-surgical conventional treatment)
Study: 12207597
Drug: Dithranol short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol short contact therapy
Study: 10476894
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for one week with bioabsorbable membrane
Study: 8229546
Drug: Timed-release 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release 5-ASA (50 mg/kg/day, maximum 3 g/day) for 8 weeks
Study: 26062916
Drug: Caffeine Ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine Ingestion (6 mg/kg BW)
Study: 23588439
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of endurance and strength training (SE; n = 22)
Study: 20378504
Drug: Cetuximab combined
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab combined with FOLFOX6 (leucovorin 5‐fluorouracil/oxaliplatin); cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly and FOLFOX6 regimen every 2 weeks consisting of oxaliplatin 85 mg/m2, LV 400 mg/m2, and 5‐FU bolus 400 mg/m2 followed by 5‐FU continuous infusion 2400 mg/m2 over 46 hours.
Study: 18564988
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on calcineurin inhibitors (CNI) and azathioprine or mycophenolate mofetil
Study: 17037284
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (ACE inhibitors, beta-antagonists, diuretics)
Study: 17037284
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aspirin (300 mg/day)
Study: 17037284
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (not specified)
Study: 10349919
Drug: Thoracic Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic Epidural Analgesia (TEA) with bupivacaine 0.125% and fentanyl 5 microg/ml
Study: 10349919
Drug: Lumbar Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar Epidural Analgesia (LEA) with morphine 0.2 microg/ml
Study: 7575771
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg once daily, increased to target levels of LDL cholesterol between 2.3 mmol/l (90 mg/dl) and 3.6 mmol/l (140 mg/dl)
Study: 7575771
Drug: Simvastatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (various dosages: 40 mg, 20 mg, 10 mg, 5 mg)
Study: 7870911
Drug: Cocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (2 mg/kg)
Study: 24474396
Drug: Adoptive cell
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive cell therapy with TIL and high-dose aldesleukin after 12 Gy TBI
Study: 20538634
Drug: Intravitreous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals)
Study: 18575048
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (ropivacaine 0.2% 10 ml, followed by an infusion of 5 ml/h for 96 hours)
Study: 18575048
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid analgesia (morphine hydrochloride 0.1 mg/kg IV every 4-6 hours as needed, with or without ketorolac trometamol up to 90 mg/day IV)
Study: 16020979
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus oral etoposide (GE group)
Study: 10493324
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 to 1800 mg/d)
Study: 10493324
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 to 75 mg/d)
Study: 1775082
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-estradiol (TTS 50) at 50 micrograms/day
Study: 7282752
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before administration of hydralazine or isosorbide dinitrate)
Study: 30802558
Drug: Trifarotene 50
Normalized name: Trifarotene 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifarotene 50 μg/g cream
Study: 24241092
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (600 mg) and vitamin E (400 IU)
Study: 21798991
Drug: One-day interval
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day)
Study: 21798991
Drug: Two-day interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days)
Study: 21798991
Drug: One-day interval
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) among women without previous vaginal deliveries
Study: 21798991
Drug: Two-day interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) among women without previous vaginal deliveries
Study: 21798991
Drug: One-day interval
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) when gestation exceeded 16 weeks
Study: 21798991
Drug: Two-day interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) when gestation exceeded 16 weeks